Activation of peroxisome proliferator-activated receptor γ in brain inhibits inflammatory pain, dorsal horn expression of Fos, and local edema

Neuropharmacology

Volumn 58, Issue 2, 2010, Pages 337-345

  Morgenweck, J ^a   Abdel aleem, O S ^a   McNamara, K C ^b   Donahue, R R ^b   Badr, M Z ^c   Taylor, B K ^b  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Allodynia; Analgesia; Hyperalgesia; Rat; Spinal cord

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 2,2 BIS(4 GLYCIDYLOXYPHENYL)PROPANE; CARRAGEENAN; DELTA12 PROSTAGLANDIN J2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PROTEIN C FOS; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ANALGESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN EDEMA; BRAIN REGION; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; HYPERALGESIA; MALE; MOTOR COORDINATION; NOCICEPTIVE STIMULATION; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION; SPINAL CORD DORSAL HORN; TREATMENT OUTCOME;

ANILIDES; ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM AGENTS; DISEASE MODELS, ANIMAL; EDEMA; EPOXY COMPOUNDS; GENE EXPRESSION; INFLAMMATION; MALE; PAIN; PPAR GAMMA; PROSTAGLANDIN D2; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD; THIAZOLIDINEDIONES;

EID: 72049114712     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2009.10.008     Document Type: Article

References (48)

1. Abdelrahman M., Sivarajah A., and Thiemermann C. Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc. Res. 65 (2005) 772-781
2. Abramoff M.D., Magelhaes P.J., and Ram S.J. Image processing with image. J. Biophotonics Int. 11 (2004) 36-42
3. Berger J., Akiyama T., and Meinke P. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol. Sci. 26 (2005) 244-251
4. Bernardo A., and Minghetti L. PPAR-gamma agonists as regulators of microglial activation and brain inflammation. Curr. Pharm. Des. 12 (2006) 93-109
5. Bishop-Bailey D., Hla T., and Warner T.D. Bisphenol A diglycidyl ether (BADGE) is a PPARgamma agonist in an ECV304 cell line. Br. J. Pharmacol. 131 (2000) 651-654
6. Brain S.D., and Cambridge H. Calcitonin gene-related peptide: vasoactive effects and potential therapeutic role. Gen. Pharmacol. 27 (1996) 607-611
7. Brightwell J.J., and Taylor B.K. Noradrenergic neurons in the locus coeruleus contribute to neuropathic pain. Neuroscience (2009)
8. Buritova J., Honore P., Chapman V., and Besson J.-M. Enhanced effects of co-administered dexamethasone and diclofenac on inflammatory pain processing and associated c-Fos expression in the rat. Pain 64 (1996) 559-568
9. Catania A., Arnold J., Macaluso A., Hiltz M.E., and Lipton J.M. Inhibition of acute inflammation in the periphery by central action of salicylates. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 8544-8547
10. Churi S.B., Abdel-Aleem O.S., Tumber K.K., Scuderi-Porter H., and Taylor B.K. Intrathecal rosiglitazone acts at peroxisome proliferator-activated receptor-gamma to rapidly inhibit neuropathic pain in rats. J. Pain 9 (2008) 639-649
11. Coggeshall R.E. Fos, nociception and the dorsal horn. Prog. Neurobiol. 77 (2005) 299-352
12. Cullingford T.E., Bhakoo K., Peuchen S., Dolphin C.T., Patel R., and Clark J.B. Distribution of mRNAs encoding the peroxisome proliferator-activated receptor alpha, beta, and gamma and the retinoid X receptor alpha, beta, and gamma in rat central nervous system. J. Neurochem. 70 (1998) 1366-1375
13. Cuzzocrea S., Pisano B., Dugo L., Ianaro A., Maffia P., Patel N.S., Di Paola R., Ialenti A., Genovese T., Chatterjee P.K., Di Rosa M., Caputi A.P., and Thiemermann C. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation. Eur. J. Pharmacol. 483 (2004) 79-93
14. D'Agostino G., La Rana G., Russo R., Sasso O., Iacono A., Esposito E., Raso G.M., Cuzzocrea S., Lo Verme J., Piomelli D., Meli R., and Calignano A. Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous peroxisome proliferator-activated receptor-alpha agonist, modulates carrageenan-induced paw edema in mice. J. Pharmacol. Exp. Ther. 322 (2007) 1137-1143
15. D'Agostino G., La Rana G., Russo R., Sasso O., Iacono A., Esposito E., Mattace Raso G., Cuzzocrea S., Loverme J., Piomelli D., Meli R., and Calignano A. Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kappaB nuclear signalling in dorsal root ganglia. Eur. J. Pharmacol. 613 (2009) 54-59
16. Devchand P.R., Keller H., Peters J.M., Vazquez M., Gonzalez F.J., and Wahli W. The PPAR-alpha-leukotriene B4 pathway to inflammation control. Nature 384 (1996) 39-43
17. Fehlberg S., Trautwein S., Goke A., and Goke R. Bisphenol A diglycidyl ether induces apoptosis in tumour cells independently of peroxisome proliferator-activated receptor-gamma, in caspase-dependent and -independent manners. Biochem. J. 362 (2002) 573-578
18. Forman L.J., Hock C.E., Harwell M., and Estilow-Isabell S. Comparison of the effects of immobilization and pressure overload induced cardiac hypertrophy on immunoreactive beta-endorphin. Life Sci. 57 (1995) 2041-2047
19. Gardner O.S., Dewar B.J., and Graves L.M. Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: an example of nongenomic signaling. Mol. Pharmacol. 68 (2005) 933-941
20. Harris J.A. Using c-fos as a neural marker of pain. Brain Res. Bull. 45 (1998) 1-8
21. Kliewer S.A., Lenhard J.M., Willson T.M., Patel I., Morris D.C., and Lehmann J.M. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83 (1995) 813-819
22. Kota B.P., H. T., and Roufogalis B.D. An overview on biological mechanisms of PPARs. Pharmacol. Res. 51 (2005) 85-94
23. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., and Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270 (1995) 12953-12956
24. Lehrke M., and Lazar M. The many faces of PPARgamma. Cell 123 (2005) 993-999
25. Lembeck F., and Holzer P. Substance P as neurogenic mediator of antidromic vasodilation and neurogenic plasma extravasation. Naunyn Schmiedebergs Arch. Pharmacol. 310 (1979) 175-183
26. Lotti T., Bianchi B., Ghersetich I., Brazzini B., and Hercogova J. Can the brain inhibit inflammation generated in the skin? The lesson of gamma-melanocyte-stimulating hormone. Int. J. Dermatol. 41 (2002) 311-318
27. LoVerme J., R. R., La Rana G., Fu J., Farthing J., Mattace-Raso G., Meli R., Hohmann A., Calignano A., and Piomelli D. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J. Pharmacol. Exp. Ther. 319 (2006) 1051-1061
28. Maeda T., Kiguchi N., Kobayashi Y., Ozaki M., and Kishioka S. Pioglitazone attenuates tactile allodynia and thermal hyperalgesia in mice subjected to peripheral nerve injury. J. Pharmacol. Sci. 108 (2008) 341-347
29. Michalik L., and Wahli W. Involvement of PPAR nuclear receptors in tissue injury and wound repair. J. Clin. Invest. 116 (2006) 598-606
30. Miyahara T., Schrum L., Rippe R., Xiong S., Yee Jr. H.F., Motomura K., Anania F.A., Willson T.M., and Tsukamoto H. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J. Biol. Chem. 275 (2000) 35715-35722
31. Moraes L.A., Piqueras L., and Bishop-Bailey D. Peroxisome proliferator-activated receptors and inflammation. Pharmacol. Ther. 110 (2006) 371-385
32. Moreno S., Farioli-Vecchioli S., and Ceru M.P. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 123 (2004) 131-145
33. Nackley A.G., Makriyannis A., and Hohmann A.G. Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 119 (2003) 747-757
34. Napimoga M.H., Souza G.R., Cunha T.M., Ferrari L.F., Clemente-Napimoga J.T., Parada C.A., Verri Jr. W.A., Cunha F.Q., and Ferreira S.H. 15d-prostaglandin J2 inhibits inflammatory hypernociception: involvement of peripheral opioid receptor. J. Pharmacol. Exp. Ther. 324 (2008) 313-321
35. Oliveira A.C., Bertollo C.M., Rocha L.T., Nascimento Jr. E.B., Costa K.A., and Coelho M.M. Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma. Eur. J. Pharmacol. 561 (2007) 194-201
36. Orlando F.L., Pena-dos-Santos D.R., Severino F.P., Pereira S.A., Rodrigues D.B., Cunha F.Q., Vieira S.M., Napimoga M.H., and Clemente-Napimoga J.T. Activation of peripheral kappa/delta opioid receptors mediates 15-deoxy-(Delta12,14)-prostaglandin J2 induced-antinociception in rat temporomandibular joint. Neuroscience 163 (2009) 1211-1219
37. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1997), Academic Press, Inc.
38. Rasband W.S. ImageJ.U.S (1997-2007), National Institutes of Health, Bethesda, Maryland, USA. http://rsb.info.nih.gov/ij
39. Ren K., and Dubner R. Descending modulation in persistent pain: an update. Pain 100 (2002) 1-6
40. Sluka K.A. Stimulation of deep somatic tissue with capsaicin produces long-lasting mechanical allodynia and heat hypoalgesia that depends on early activation of the cAMP pathway. J. Neurosci. 22 (2002) 5687-5693
41. Sundararajan S., Jiang Q., Heneka M., and Landreth G. PPARgamma as a therapeutic target in central nervous system diseases. Neurochem. Int. 49 (2006) 136-144
42. Tan N.S., Michalik L., Desvergne B., and Wahli W. Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes. J. Steroid Biochem. Mol. Biol. 93 (2005) 99-105
43. Taylor B.K., Holloway D., and Printz M.P. A unique central cholinergic deficit in the spontaneously hypertensive rat: physostigmine reveals a bradycardia associated with sensory stimulation. J. Pharmacol. Exp. Ther. 268 (1994) 1081-1090
44. Taylor B.K., Dadia N., Yang C.B., Krishnan S., and Badr M. Peroxisome proliferator-activated receptor agonists inhibit inflammatory edema and hyperalgesia. Inflammation 26 (2002) 121-127
45. Taylor B.K., Kriedt C., Nagalingam S., Dadia N., and Badr M. Central administration of perfluorooctanoic acid inhibits cutaneous inflammation. Inflamm. Res. 54 (2005) 235-242
46. Urban M.O., and Gebhart G.F. Supraspinal contributions to hyperalgesia. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 7687-7692
47. Victor N.A., Wanderi E.W., Gamboa J., Zhao X., Aronowski J., Deininger K., Lust W.D., Landreth G.E., and Sundararajan S. Altered PPARgamma expression and activation after transient focal ischemia in rats. Eur. J. Neurosci. 24 (2006) 1653-1663
48. Wright H.M., Clish C.B., Mikami T., Hauser S., Yanagi K., Hiramatsu R., Serhan C.N., and Spiegelman B.M. A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation. J. Biol. Chem. 275 (2000) 1873-1877